Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)

Inclusion Criteria: * Patients must be age 50 years or older * Patients must have predominantly classic, minimally classic or occult with no classic lesions secondary to Age Related Macular Degeneration. * The study eye must have ETDRS best corrected visual acuity of 69 to 24 letters (20/40 to 20/320 Snellen equivalent). * Patients must be willing and able to return for scheduled monthly follow-up visits for two-years. Exclusion Criteria: * Prior pharmacologic treatment for AMD in the study (patients can not have previously received Avastin®/Lucentis®, Macugen®, or any other anti-VEGF agents, steroid treatments, PDT, radiation treatment, or any experimental therapies for AMD in the study eye) * Any intraocular surgery of the study eye within 12 weeks of screening * Previous posterior vitrectomy of the study eye * Advanced glaucoma or intraocular pressure above 22 mm Hg in the study eye despite treatment.